The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179518 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Stella Bouziana und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, King's College Hospital, London SE59RS, UK. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T-cell therapies have revolutionised the field of haematological malignancies by achieving impressive remission rates in patients with highly refractory haematological malignancies, improving overall survival. To date, six commercial anti-CD19 and anti-BCMA CAR T-cell products have been approved by the Food and Drug Administration (FDA) for the treatment of relapsed/refractory B-cell haematological malignancies and multiple myeloma. The indications for CAR T-cell therapies are gradually expanding, with these therapies being investigated in a variety of diseases, including non-malignant ones. Despite the great success, there are several challenges surrounding CAR T-cell therapies, such as non-durable responses and high-grade toxicities. In addition, a new safety concern was added by the FDA on 28 November 2023 following reports of T-cell malignancies in patients previously treated with either anti-CD19 or anti-BCMA autologous CAR T-cell therapies both in clinical trials and in the real-world setting. Since then, several reports have been published presenting the incidence and analysing the risks of other secondary malignancies after CAR T-cell therapies. In this opinion article, the current landscape of secondary malignancies after CAR T-cell therapies is presented, along with a proposed strategy for future research aiming at potentially diminishing or abrogating the risk of developing secondary malignancies after CAR T-cell therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, King's College Hospital, London SE59RS, UK.
- BReMeL, Biopharmaceutical and Regenerative Medicine Laboratories, 55534 Thessaloniki, Greece.
ORCID-Profile: Stella Bouziana, Dimitrios Bouzianas
Zitieren
APA
Bouziana, S., & Bouzianas, D. (2024). The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179518
Vancouver
Bouziana S, Bouzianas D. The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179518
BibTeX
@article{Bouziana2024,
author = {Bouziana, Stella and Bouzianas, Dimitrios},
title = {The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179518}
}
EUVIMED